Purpose: To determine the potential effect of Chikusetsu saponin IVA (CS-IVA) on benign prostatic hyperplasia (BPH), as well mechanism action.
 Methods: Benign epithelial cell response to treatment by CS-IVA was evaluated 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), colony formation assay, and cycle analysis. Flow cytometry immunoblot assay were used assess apoptosis...

Lower urinary tract symptoms from benign prostatic hyperplasia are a very prevalent disease process which affects more than 40% of men over age 60. When LUTS from BPH become medically refractory, transurethral resection of the prostate and prostatectomy have been the gold standards for treatment. While the efficacy of these procedures has been clearly delineated, they are also associated with s...

The prevalence and incidence of clinical problems secondary to and associated with benign prostatic hyperplasia (BPH) have been increasing as the population ages. Men with lower urinary tract obstruction (LUTS) may have sexual dysfunction, including ejaculatory loss, painful ejaculation, and sometimes erectile dysfunction (ED). Even though, the pathogenic relationship between BPH and these symp...

The purpose of this research is to carry out a quantitative study of prostate-specific antigen dynamics for patients with prostatic diseases, such as benign prostatic hyperplasia (BPH) and localized prostate cancer (LPC). The proposed PSA mathematical model was implemented using clinical data of 218 Japanese patients with histological proven BPH and 147 Japanese patients with LPC (stages T2a an...

BACKGROUND In 2003, a 74-item quality-of-life (QOL) scale for Chinese benign prostatic hyperplasia (BPH) patients (BPH-QLS) was developed. Although the scale displayed good reliability and validity, the time required to complete it may limit its use. The purpose of this study was to construct and validate a short-form quality-of-life (QOL) scale for Chinese patients with Benign Prostatic Hyperp...

The aim of this study was to evaluate the therapeutic efficacy of Qianliening capsule (QC) against benign prostatic hyperplasia (BPH) in vivo in a BPH rat model, as well as to investigate the effects of QC on prostatic cell apoptosis and the possible molecular mechanisms mediating its anti-BPH activity. Fifty male Sprague‑Dawley (SD) rats were ran...

The present study investigated the histological prevalence of subclinical prostatic disease in a canine mixed-breed population. The reliability of digital rectal examination (DRE) as a screening test for subclinical prostatic disease was also evaluated. DRE was performed on 500 male dogs (age range 1 to 21 years) before the dogs died of diseases not related to the prostate. Necropsies of these ...

'UroLift' has emerged as a new minimally-invasive nonablative surgical technique for benign prostatic hyperplasia (BPH). We discuss the procedure, cost, evidence, advantages and disadvantages of this procedure. It is a novel technology suitable for a selected group of patients that allows for a bespoke treatment for men with BPH.

Current theraputic options for the treatment of symptomatic benign prostatic hyperplasia (BPH) are reviewed. Therapeutic options for mild lower urinary tract symptoms (LUTS), as defined by the American Urological Association, are generally treated medically. Moderate to severe LUTS can be treated medically or with surgical therapy. Current medical and surgical treatments for LUTS secondary to B...

Large-conductance Ca(2+)-activated K(+) (BK(Ca)) channel encoded by K(Ca)1.1 plays an important role in the control of smooth muscle tone by modulating membrane potential and intracellular Ca(2+) mobilization. BK(Ca) channel is functionally expressed in prostatic smooth muscle cells, and is activated by α(1)-adrenoceptor agonists. The main objective of this study was to elucidate the pathophysi...